Quality Systems – Page 75

Inconsistent global strategy during agency query response – how to avoid repeat deficiencies

Strategies to Address Inconsistencies in Global Agency Query Responses and Mitigate Future Deficiencies In the increasingly complex landscape of pharmaceutical manufacturing and regulatory compliance, an inconsistent global strategy during agency…

Utilities excursion event during inspection walkthrough – how to defend maintenance decisions to inspectors

Investigating Utilities Excursion Events During Inspection Walkthroughs During regulatory inspections, utilities excursion events can pose significant challenges for pharmaceutical operations. These excursions often catch teams off guard and may lead…

Deficiency response rejected by agency during agency query response – how to avoid repeat deficiencies

Addressing Agency Rejections of Deficiency Responses: Strategies to Prevent Recurrence In the pharmaceutical industry, a rejection of a deficiency response during an agency query can be a significant setback, indicating…

Preventive maintenance overdue during changeover maintenance – preventing repeat deviations via reliability strategy

Strategies to Address Preventive Maintenance Backlogs During Changeover Procedures In pharmaceutical manufacturing, the integrity of operations is heavily reliant on systematic and timely preventive maintenance (PM). A common challenge faced…

Commitment timelines missed during inspection preparation – FDA/EMA expectations and how to respond

Responding to Commitment Timeline Failures in Pharmaceutical Inspection Preparations Pharmaceutical companies often face challenges during regulatory inspections, especially when commitment timelines are missed. These lapses can result in significant scrutiny…

Recurring equipment stoppages during aseptic support activities – how to defend maintenance decisions to inspectors

Addressing Repeated Equipment Interruptions During Aseptic Support Tasks: A Guide for Inspectors Recurring equipment stoppages during aseptic support activities can pose significant challenges for pharmaceutical manufacturers, impacting productivity and compliance.…

Inconsistent global strategy during post-approval maintenance – approval risk analysis and mitigation

Addressing Inconsistent Global Strategies in Post-Approval Maintenance: An EMA Perspective on Investigations and Mitigation The pharmaceutical landscape is laden with complexities, especially during post-approval maintenance where regulatory compliance is critical.…

Utilities excursion event during inspection walkthrough – GMP documentation expectations for engineering teams

Evaluating Utilities Excursion Events During Inspection Walkthroughs: A Guide for Engineering Teams Utilities excursion events can significantly impact pharmaceutical operations, particularly during critical inspection walkthroughs. These events, often related to…

Agency feedback misinterpreted during lifecycle management – how to avoid repeat deficiencies

How to Prevent Misinterpretation of Agency Feedback During Lifecycle Management Misinterpretation of agency feedback during lifecycle management presents a significant challenge for pharmaceutical companies, leading to repeated deficiencies during inspections,…

CMMS records incomplete during inspection walkthrough – calibration/PM evidence pack checklist

Addressing Incomplete CMMS Records During Regulatory Inspections When regulatory agencies like the FDA, EMA, or MHRA conduct inspections, complete and accurate documentation is crucial. A common challenge encountered by pharmaceutical…

Submission delayed due to data gaps during post-approval maintenance – CAPA and strategy reset

Addressing Submission Delays Caused by Data Gaps During Post-Approval Maintenance In the pharmaceutical manufacturing landscape, submission delays can significantly impact a company’s credibility and compliance standing with regulatory authorities. Delays…

Submission delayed due to data gaps during post-approval maintenance – CAPA and strategy reset

Addressing Delays in Submission Due to Data Gaps in Post-Approval Maintenance Pharmaceutical companies frequently encounter delays during the submission process primarily caused by data gaps that arise in post-approval maintenance.…